Celgene to look beyond Revlimid at R&D day

During Celgene's R&D day tomorrow--the first it has hosted in five years--the developer will attempt to show analysts that it has a promising drug pipeline beyond Revlimid, its top-selling multiple myeloma drug. Revlimid and its predecessor drug Thalomid accounted for almost 80 percent of the biotech's sales last year. Specifically, Reuters says Celgene will detail its programs for "lung cancer; chemotherapy-induced anemia; multiple myeloma; Crohn's disease, a gastrointestinal disorder; psoriasis, a skin disorder; and psoriatic arthritis."

Analysts are also waiting to see if Celgene will produce data supporting Revlimid as a maintenance treatment for multiple myeloma. That could boost the drug's sales from $1.7 billion in 2009 to $3.8 billion by 2013. The drug is also in clinical trials for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, prostate cancer and colorectal cancer.

- read this item for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.